This monoclonal antibody can specifically bind to human Prominin-1 (CD133). It also shows a potential effect on tumor growth inhibition including head and neck cancer, glioblastoma and breast cancer.
Figure 1 Specificity of clone 7.
Cells were incubated with either clone 7 or 293C3 (Militenyi) primary antibody, followed by incubation with a labeled secondary antibody, and then analyzed by flow cytometry. The newly developed anti-CD133 clone 7 (open black histogram) stains very specifically the CD133-overexpressing cells, Caco-2 (iii), GBM6 (iv) and U87 cells transfected with CD133 (ii) but not CD133 negative U87 cells (i). Immunostaining of clone 7 is compared to clone 293C3 (open grey histogram). Isotype control is represented by solid grey histogram.
Figure 2 Specificity of clone 7.
Tunicamycin mediated glycosylation inhibition: Caco-2 cells were treated with increasing doses of tunicamycin (2.5, 5, 10 and 20 μg/ml) for 3 days. DMSO treated cells or untreated cells served as controls. Cells were lysed and then analyzed by western blotting using clone 7 or GAPDH antibodies.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For research use only. Not intended for any clinical use.